"A large-scale genomic analysis found that non-inherited mutations in hundreds of genes together account for about 1 in 10 cases of severe congenital heart defects. The findings bring us closer to understanding the most common type of birth defect"...
- Patient Information:
Details with Side Effects
RYTHMOL SR® is indicated to prolong the time to recurrence of symptomatic atrial fibrillation (AF) in patients with episodic (most likely paroxysmal or persistent) AF who do not have structural heart disease.
- The use of RYTHMOL SR in patients with permanent AF or in patients exclusively with atrial flutter or paroxysmal supraventricular tachycardia (PSVT) has not been evaluated. Do not use RYTHMOL SR to control ventricular rate during AF.
- Some patients with atrial flutter treated with propafenone have developed 1:1 conduction, producing an increase in ventricular rate. Concomitant treatment with drugs that increase the functional atrioventricular (AV) nodal refractory period is recommended.
- The effect of propafenone on mortality has not been determined [see BOXED WARNING].
DOSAGE AND ADMINISTRATION
RYTHMOL SR can be taken with or without food. Do not crush or further divide the contents of the capsule.
The dose of RYTHMOL SR must be individually titrated on the basis of response and tolerance. Initiate therapy with RYTHMOL SR 225 mg given every 12 hours. Dosage may be increased at a minimum of 5 day interval to 325 mg given every 12 hours. If additional therapeutic effect is needed, the dose of RYTHMOL SR may be increased to 425 mg given every 12 hours.
In patients with hepatic impairment or those with significant widening of the QRS complex or second or third degree AV block, consider reducing the dose.
The combination of CYP3A4 inhibition and either CYP2D6 deficiency or CYP2D6 inhibition with the simultaneous administration of propafenone may significantly increase the concentration of propafenone and thereby increase the risk of proarrhythmia and other adverse events. Therefore, avoid simultaneous use of RYTHMOL SR with both a CYP2D6 inhibitor and a CYP3A4 inhibitor, [see WARNINGS AND PRECAUTIONS and DRUG INTERACTIONS].
Dosage Forms and Strengths
RYTHMOL SR (propafenone HC1) capsules are supplied as white, opaque, hard gelatin capsules containing 225 mg, 325 mg, or 425 mg of propafenone HC1 and imprinted in red with the Reliant logo and strength. The 325 mg strength is also imprinted with a single red band around % of the circumference of the body; the 425 mg strength is imprinted with three bands around % of the circumference of the body.
RYTHMOL SR (propafenone HC1) capsules are supplied as white, opaque, hard gelatin capsules containing either 225 mg, 325 mg, or 425 mg of propafenone HC1 and imprinted in red with the Reliant logo and strength. The 325 mg strength is also imprinted with a single red band around % of the circumference of the body; the 425 mg strength is imprinted with three bands around % of the circumference of the body.
|Capsule Strength||60 count bottle NDC|
Storage: Store at 25°C (77°F); excursions permitted to 15° to 30°C (59° to 86°F). Dispense in a tight container.
Manufactured for: GlaxoSmithKline, Research Triangle Park, NC 27709. Manufactured by: Abbott Laboratories North Chicago, IL 60064. Revised: 4/2011
Last reviewed on RxList: 6/1/2011
This monograph has been modified to include the generic and brand name in many instances.
Additional Rythmol SR Information
Rythmol SR - User Reviews
Rythmol SR User Reviews
Now you can gain knowledge and insight about a drug treatment with Patient Discussions.
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Get the latest treatment options.